PubMed Health⌕ Search

Biomedical subjects

R Minervini

Publications and source records attributed to R Minervini.

At least 37 records · Page 2Linked to original sources
PubMed1995

Vacuum constriction device and topical minoxidil for management of impotence.

OBJECTIVE: We report our preliminary experience with a vacuum constriction device and topical minoxidil for the management of impotence. METHODS: We evaluated 18 patients, 8 with neurogenic and 10 with psychogenic impotence with a vacuum constriction device and topical minoxidil (1 ml 2% solution). RESULTS AND CONCLUSIONS: All patients responded to treatment but 100 cases refused home use because of psychological impact. Twelve patients did not need the application of the constrictive ring because of the erection facilitation effect of minoxidil. No side effects were observed. In our opinion the association of the vacuum constriction device with topical minoxidil might be useful in the treatment of impotence; however, several factors must be evaluated in selecting patients. Application of minoxidil before vacuum constriction device might be useful to reduce the time of device application, to increase the efficacy of the device and in some cases to avoid the use of the constrictive ring.

Administration, Topical↗
PubMed1994

Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up.

Mitomycin C (MMC) was given intravesically to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS) between 1985 and 1989. Of the 10 patients with complete response two presented progression during the follow-up: one of them in T2 at the 32nd month, and one had a relapse of CIS with diffusion to the prostatic urethra at the 34th month: both patients underwent cystectomy. One patient died of an unrelated cause. At the 48th month 5 out of 7 patients were free from neoplasm. Neoplastic recurrence occurred in 3 patients: one responded to a second endoscopic resection and instillation of MMC, two presented further recurrences. Two patients underwent cystectomy: one for neoplastic progression and one for involvement of the prostatic urethra. MMC seems to be effective in the treatment of CIS of the urinary bladder and the unresponsiveness to chemotherapy must be considered as an adverse prognostic factor for the progression of the neoplasm.

Administration, Intravesical↗
PubMed1994

Cellular expression of lymphocyte function-associated antigen-1 and intercellular adhesion molecule-1 in normal kidney structures and in renal cancer. Possible significance in immune response and in the clinicopathological correlation.

In this study we investigated the presence of lymphocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) on renal cell cancer in 16 patients who underwent nephrectomy. In all cases, normal renal tissues presented ICAM-1 on the parietal epithelial cells lining Bowman's capsule while neither the visceral epithelium nor the glomerular endothelium were stained. The epithelial proximal and distal tubular cells were stained poorly (5 +/- 3 positive tubular cross sections/mm2). No renal cells were stained by the monoclonal antibody for LFA-1. In contrast, in renal cancer tissue we found 6 cases, negative for ICAM-1 and the others positive with a mean number of positive tubular cross sections of 52 +/- 37/mm2. In 10 cases staining with LFA-1 antibody was negative, while for the other cases the mean number of positive tubular cross sections was 11 +/- 8/mm2. Our results suggest that the expression of ICAM-1 and LFA-1 on the surface of malignant cells may explain the unusual clinical aspects of renal cell carcinoma, its association with the immune system, and clarify certain aspects of immunotherapy.

Carcinoma, Renal Cell↗
PubMed1994

[Role of color-Doppler in the assessment of erectile impotence: personal experience].

We present our experience with colour duplex sonography in the assessment of 38 impotent men, whose ten underwent radical prostatectomy, following intracavernous pharmacological stimulation with PGE1. All patients with a clinical good response following PGE1 injection had peak cavernosal artery velocities > 30 cm/sec. The remaining suboptimal responders who presented an elevated end-diastolic velocity (> 5 cm/sec) showed a venous leakage demonstrated with cavernosography. Colour duplex sonography is a valuable and non-invasive tool in the assessment of impotence and can provide valuable information in the diagnosis of vasculogenic erectile dysfunction.

Aged↗
PubMed1994

Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up.

Mitomycin C (MMC) was given intravesically over a period of 36 months to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS). Initial complete response was obtained in 10 patients. Of these patients, 5 presented recurrences; one in T2 at the 32nd month, one had a relapse of CIS with diffusion to the prostatic urethra at the 34th month: both patients underwent cystectomy. The remaining three patients presented Ta or T1 relapses and underwent endoscopic resection and a new instillation of MMC. The 4 patients who did not respond were treated with a new instillation of MMC:3 were unsuccessful and underwent cystectomy (one at the 9th month, one at the 12th month for progression to T2 and one at the 14th month for involvement of the prostatic urethra); the 4th patient responded to the treatment but at the 14th month had a relapse of CIS and he underwent cobalt-therapy. At the 36th month, 7 out of 13 patients were free from neoplasm. A neoplastic progression occurred in 3 patients: one out of the 9 patients who responded to the treatment and two out of the 4 who did not respond. Diffusion to the prostatic urethra was observed in 2 of the 13 patients; one patient responded to MMC and the other did not. Five patients underwent cystectomy: 3 for neoplastic progression and 2 for involvement of the prostatic urethra. MMC seems to be effective for the treatment of CIS of the urinary bladder and the absence of a response to chemotherapy must be considered an adverse prognostic factor for the neoplastic progression.

Administration, Intravesical↗
PubMed1993

Trigonoplasty by Gil Vernet in the treatment of vesicoureteral reflux in adult patients.

There are several surgical procedures for the correction of primary vesicoureteral reflux. Among them, the one of increasing success for its safety and effectiveness is that introduced by Gil Vernet at the beginning of the 1980s, primarily in the pediatric field. By the time of this study, its use had been extended to adult patients as well. We report the results obtained with this method in 17 adult patients with primary vesicoureteral reflux.

Adolescent↗
PubMed1993

Self-retaining intraurethral device for treatment of prostatic obstruction.

We report our experience about insertion of 32 self-retaining intraurethral device (IUC) in patients with prostatic obstruction. Follow-up ranged between 2 and 38 weeks. Success rate of IUC insertion was 93.7% and 46.6% of patients have IUC in place without complications during follow-up. IUC is easy and quick to introduce, it allows spontaneous voiding, full continence, sexual activity and routine life-style. It represents a useful alternative to indwelling catheter in patients at high risk or refusing surgery and it might be used in patients who are waiting for surgery or need long term catheterization.

Aged↗
PubMed1993

[Local hyperthermia in the treatment of benign prostatic diseases].

Local Prostatic Hyperthermia is a 8 year old procedure that has been used for treating benign prostatic hypertrophy, chronic non bacterial prostatitis and prostatic carcinoma. We treated 80 patients affected by benign prostatic diseases who referred to our Clinic from November 1990 to December 1991. 42 patients were affected by benign prostatic hypertrophy (7 of them with permanent bladder catheter) and 18 patients were affected by chronic non bacterial prostatitis. A 915 Mhz microwaves generator apparatus with endorectal probe and cooling circuit has been used. The criteria we used to include patients in treatment were the following: high operating risk, the refusing of the operation, a prostatic volume bigger than 180 cc and finally a rectum thick less than 10 mm. All patients underwent preliminary echographic, hematic , urodynamic and rectoscopic exams. A prostatic biopsy was taken at the beginning and at the end of the treatment. During every session, which lasted sixty minutes and was repeated twice a week, we applied a temperature of 42 C degrees in patients with benign prostatic hypertrophy, and a temperature of 41 C degree in those with chronic non bacterial prostatis. Patients were checked with the same echographic and urodynamic parameters three months, six months and 1 year after the treatment. Subjective and objective symptoms improved in 65% of cases, and we also noticed a 50% reduction of post-urination residue, with an increase of maximal urinary flux. We also noticed a decrease of the dysuria and nycturia.(ABSTRACT TRUNCATED AT 250 WORDS)

Chronic Disease↗
PubMed1984

Mesonephric adenocarcinoma of bladder.

Mesonephric adenocarcinoma of the bladder is an extremely rare neoplasm. The typical location in the bladder neck and trigone tends to confirm that this neoplasm probably derives from a remanent of the mesonephric duct. This case is the fourth described in the literature. The patient underwent total cystectomy with ureterosigmoidostomy and is still apparently tumor free 7 years after operation.

Humans↗
PubMed1984

Elevated free cortisol plasma levels in patients with prostatic carcinoma undergoing treatment with estrogens.

The total cortisol concentration (TCC), the percentage of free cortisol (%FC) and the apparent free plasma cortisol concentration (AFCC) have been determined in plasma samples of 9 patients affected by prostatic carcinoma undergoing treatment with estrogens measured by an equilibrium dialysis system and a radioimmunological method. The values found in this group of patients were compared to those obtained in 9 untreated control patients and in normal healthy persons. The mean TCC values found in treated patients were significantly higher than in the controls, both in basal condition (circadian rhythm) and after dynamic tests, while the mean %FC values were significantly lower than the controls except for the results obtained after an ACTH stimulation test. The mean AFCC values in treated patients were elevated both in basal condition and after the dexamethasone suppression test (DST), but the difference between the two groups of patients was statistically significant only after DST. This study demonstrates that patients with prostatic carcinoma undergoing treatment with estrogens can have markedly increased free plasma cortisol levels with an impairment of the hypothalamus-pituitary-adrenal axis.

Adrenocorticotropic Hormone↗
PubMed1983

Total cystectomy and ureterosygmoidostomy for carcinoma of the bladder.

The results obtained in a series of 233 subjects who underwent surgery for total cystectomy and ureterosygmoidostomy for carcinoma of the bladder are analyzed. The immediate and long-term results, the complications and length of survival, both in general and in relation to the stage of the neoplasia, have been considered. The surgical death rate was 7%. Survival, taking all cases into account, was 80% after 1 year, 55% after 3 years, 36% after 5 years and 8.3% after 10 years. Significant differences in survival were found among those patients with pathologic stage PIS-P1-P2 and those with P3-P4. From a survival of 64% after 5 years in the first group, we pass to 23% for P3 and 0% for P4. The precocious complications are anastomosis stenosis (1.8%), uro-fecal fistulae (1.8%) and urinary fistulae (1.4%). Late complications are anastomosis stenosis (13.6%), pyelonephritis with episodes of fever (19.3%), severe acidosis (1.8%) and kidney stones (1.8%).

Adult↗